
Search Clinical Trials
Sponsor Condition of Interest |
---|
A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor
Praxis Precision Medicines
Essential Tremor
This multi-center, randomized, double-blinded, placebo-controlled, dose-range-finding
clinical trial (with an optional Extension comprised of an Extension Double-blind (DB) Lead
in Period followed by an Extension Open-label (OL) Period) that will assess the efficacy,
safety,... expand
This multi-center, randomized, double-blinded, placebo-controlled, dose-range-finding clinical trial (with an optional Extension comprised of an Extension Double-blind (DB) Lead in Period followed by an Extension Open-label (OL) Period) that will assess the efficacy, safety, and tolerability of PRAX 944 in participants aged 18 years or older who have a diagnosis of Essential Tremor (ET) and have had symptoms for at least 3 years. Type: Interventional Start Date: Oct 2021 |
AMPLATZER PFO Occluder Post Approval Study
Abbott Medical Devices
Stroke
Patent Foramen Ovale
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness
of the AMPLATZER™ PFO Occluder in the post Approval Setting.
expand
The purpose of this single arm, multi-center study is to confirm the safety and effectiveness of the AMPLATZER™ PFO Occluder in the post Approval Setting. Type: Interventional Start Date: Jan 2018 |
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and...
Celgene
Multiple Myeloma
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study
consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in
combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX
and BTZ and... expand
This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combination with DEX and BTZ and CC-220 in combination with DEX and CFZ; and the expansion of the RP2D (Part 2) for CC-220 in combination with DEX for Relapsed Refractory Multiple Myeloma and CC-220 in combination with DEX and BTZ for Newly Diagnosed Multiple Myeloma. Type: Interventional Start Date: Oct 2016 |
Treatment of POEMS Syndrome With Daratumumab
University of Arkansas
POEMS Syndrome
This trial investigates the use of Daratumumab (DARA), an antibody directed at the human
cluster of differentiation 38 (CD38) molecule, for the treatment of patients with
Polyneuropathy, Organomegaly, Endocrinopathy, m Protein Component, Skin Changes (POEMS)
syndrome. This... expand
This trial investigates the use of Daratumumab (DARA), an antibody directed at the human cluster of differentiation 38 (CD38) molecule, for the treatment of patients with Polyneuropathy, Organomegaly, Endocrinopathy, m Protein Component, Skin Changes (POEMS) syndrome. This trial will enroll ten subjects, who will complete 12 four-week cycles of DARA, in combination with the immunomodulatory drug (IMiD) lenalidomide. Objectives of this study include improvement in neuropathy and performance status, as well as improvement in laboratory values and survival. Type: Interventional Start Date: Sep 2020 |
SPRINT® Peripheral Nerve Stimulation for the Treatment of Back Pain
SPR Therapeutics, Inc.
Low Back Pain
Back Pain
The purpose of this study is to compare standard of care treatments for back pain to
electrical stimulation. Stimulation is delivering small amounts of electricity to the nerves
in your low back. This study will use a device called the SPRINT Peripheral Nerve Stimulation
(PNS)... expand
The purpose of this study is to compare standard of care treatments for back pain to electrical stimulation. Stimulation is delivering small amounts of electricity to the nerves in your low back. This study will use a device called the SPRINT Peripheral Nerve Stimulation (PNS) System. The device is cleared by the FDA for up to 60 days of use for the relief of chronic or acute pain (including back pain) Type: Interventional Start Date: Jun 2020 |
Pyruvate Kinase Deficiency Global Longitudinal Registry
Agios Pharmaceuticals, Inc.
Pyruvate Kinase Deficiency
This study is an observational (ie, noninterventional), longitudinal, multicenter, global
registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic
anemia.
This Registry will be open for enrollment for 7 years and all enrolled participants... expand
This study is an observational (ie, noninterventional), longitudinal, multicenter, global registry for patients with pyruvate kinase (PK) deficiency, a rare nonspherocytic hemolytic anemia. This Registry will be open for enrollment for 7 years and all enrolled participants will be followed prospectively for a minimum of 2 years, and up to 9 years. Data will be collected from participating Registry Physicians, participants, and, where appropriate, parents/guardians who have provided informed consent or assent (where relevant) and authorization pursuant to applicable laws and regulations. Data should include demographic, clinical, and treatment data; and other data of relevance to the management of patients with PK deficiency. Annual chart review and data entry are expected in order to enhance longitudinal understanding of PK deficiency; however, no specific protocol schedule of assessment is required by this Registry protocol. Type: Observational [Patient Registry] Start Date: Apr 2018 |
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis...
Savara Inc.
Autoimmune Pulmonary Alveolar Proteinosis
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to
receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects
completing the 48 week placebo-controlled period will receive open-label treatment with once
daily... expand
160 subjects with autoimmune pulmonary alveolar proteinosis (aPAP) will be randomized to receive once daily treatment with inhaled molgramostim or placebo for 48 weeks. Subjects completing the 48 week placebo-controlled period will receive open-label treatment with once daily inhaled molgramostim for 48 weeks. Type: Interventional Start Date: May 2021 |
A Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Target PharmaSolutions, Inc.
Hepatocellular Cancer
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual
clinical practice. TARGET-HCC will create a research registry of participants with HCC within
academic and community real-world practices in order to assess the safety and effectiveness... expand
TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations. Type: Observational [Patient Registry] Start Date: Dec 2016 |
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib,...
National Cancer Institute (NCI)
Endometrial Undifferentiated Carcinoma
Endometrioid Adenocarcinoma
Recurrent Endometrial Serous Adenocarcinoma
Recurrent Uterine Corpus Cancer
Stage IV Uterine Corpus Cancer AJCC v7
This phase II trial studies the effects of the combination of olaparib and durvalumab,
cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients
with endometrial cancer that has come back (recurrent) or does not respond to treatment
(refractory).... expand
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back (recurrent) or does not respond to treatment (refractory). Olaparib, cediranib, and capivasertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Testing the combinations may lower the chance of endometrial cancer growing or spreading compared to usual care. Type: Interventional Start Date: Sep 2018 |
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment...
NRG Oncology
Prostate Adenocarcinoma
This phase III trial uses the Decipher risk score to guide intensification (for higher
Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better
match therapies to an individual patient's cancer aggressiveness. The Decipher risk score
evaluates... expand
This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better match therapies to an individual patient's cancer aggressiveness. The Decipher risk score evaluates a prostate cancer tumor for its potential for spreading. In patients with low risk scores, this trial compares radiation therapy alone to the usual treatment of radiation therapy and hormone therapy (androgen deprivation therapy). Radiation therapy uses high energy x-rays or particles to kill tumor cells and shrink tumors. Androgen deprivation therapy blocks the production or interferes with the action of male sex hormones such as testosterone, which plays a role in prostate cancer development. Giving radiation treatment alone may be the same as the usual approach in controlling the cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy. In patients with higher Decipher gene risk, this trial compares the addition of darolutamide to usual treatment radiation therapy and hormone therapy, to usual treatment. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Type: Interventional Start Date: Nov 2021 |
Developing a Test for the Detection of Ovarian Cancer
Massachusetts General Hospital
Ovarian Neoplasms
Ovarian Epithelial Carcinoma
Fallopian Tube Neoplasms
High Grade Ovarian Serous Adenocarcinoma
Stage I Ovarian Cancer
The study aims to develop a test for early detection of ovarian cancer using DNA from a
growth involving the ovary found in a washing of the uterus (womb), and proteins found in the
blood. The samples of the wash and the blood will be taken before surgery. After surgery,
doctors... expand
The study aims to develop a test for early detection of ovarian cancer using DNA from a growth involving the ovary found in a washing of the uterus (womb), and proteins found in the blood. The samples of the wash and the blood will be taken before surgery. After surgery, doctors will determine whether the participant had ovarian cancer or a benign disease of the ovaries. The tests of the washings and the blood will be examined to see how much the participants with ovarian cancer can be separated from the participants with a benign ovarian disease by the tests. Small amounts from the washing and the blood samples will be sent to four sites for analysis. Statistical analyses of these data will compare tumor DNA found in the washing of the uterus with proteins in the blood to detect cases of ovarian cancer. The primary goal is to find tests that are mostly positive for cases of ovarian cancer and mostly negative for patients with benign disease. It is hoped that if the tests work for participants with symptoms of the disease that these tests will also work when testing women who have no symptoms. A new study would be needed to see if the tests worked in this situation. If the tests work, this could lead to increasing the number of cases detected in early stage disease and decreasing the number of cases detected in late stage disease. If this change in late stage is large, it will likely reduce deaths due to ovarian cancer. Type: Observational Start Date: Apr 2020 |
Vaccination of High Risk Breast Cancer Patients
University of Arkansas
Breast Cancer
Breast Neoplasms
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in
combination with standard neoadjuvant chemotherapy and surgery in patients with clinical
stage I, II or III estrogen-receptor (ER)-positive, HER2-negative breast cancer.
expand
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III estrogen-receptor (ER)-positive, HER2-negative breast cancer. Type: Interventional Start Date: Jan 2015 |
Impact of a POPOP on Preoperative Health, Eligibility, and Clinical & Patient-Reported Outcomes in TJA
University of Arkansas
Osteoarthritis, Knee
Osteoarthritis, Hip
Avascular Necrosis
Rheumatoid Arthritis
In this pilot study, we will test the hypothesis that a POPOP for currently ineligible UAMS
orthopedic surgery patients wanting hip or knee replacement improves markers of preoperative
health, ability to reach a BMI threshold <40 kg/m2 required for surgical eligibility, and... expand
In this pilot study, we will test the hypothesis that a POPOP for currently ineligible UAMS orthopedic surgery patients wanting hip or knee replacement improves markers of preoperative health, ability to reach a BMI threshold <40 kg/m2 required for surgical eligibility, and postoperative outcomes versus SOC. Type: Interventional Start Date: Jan 2022 |
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
InterveXion Therapeutics, LLC
Methamphetamine Intoxication (Disorder)
The hypothesis of this multisite Phase 2a study is that IXT-m200 will be well-tolerated in
patients with acute mild to moderate METH toxicity. A randomized, open label design will be
used in which one dose of IXT-m200 will be compared to treatment-as-usual (TAU).
Approximately... expand
The hypothesis of this multisite Phase 2a study is that IXT-m200 will be well-tolerated in patients with acute mild to moderate METH toxicity. A randomized, open label design will be used in which one dose of IXT-m200 will be compared to treatment-as-usual (TAU). Approximately 40 participants will be enrolled in 4 cohorts. A dose escalation approach will be used so that progressively higher IXT-m200 doses will be evaluated in each cohort. In conjunction with safety monitoring, this design assures the opportunity to observe early safety findings before any participants are exposed to the next higher dose. The randomization ratio for IXT-m200 versus TAU is defined as 4:1 for each cohort so that the number of participants receiving TAU equals the number receiving each dose of IXT-m200 at the end of the study. Agitation scales and vital signs will be recorded to track effect of the antibody treatment versus TAU over time on agitation associated with METH use. While in the emergency department (ED), detailed and pertinent medical and psychiatric histories, and physical exam will be obtained, along with laboratory assessments and ECGs. In the ED, participants will give blood samples for analysis of METH and IXT-m200 concentrations and followed for development of adverse events. Participants will be evaluated at 2 days and 4 weeks after discharge from the ED for adverse events and drug use history. Cohort escalation reviews will be performed by the Sponsor, Medical Monitor, and Data and Safety Monitoring Board (DSMB) between cohorts and the next group will not start until after completion of this review. Type: Interventional Start Date: Jun 2021 |
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic...
Southwest Oncology Group
Castration Levels of Testosterone
Metastatic Prostatic Adenocarcinoma
Stage IV Prostate Cancer AJCC v8
Stage IVA Prostate Cancer AJCC v8
Stage IVB Prostate Cancer AJCC v8
This phase III trial studies how well standard systemic therapy with or without definitive
treatment (prostate removal surgery or radiation therapy) works in treating participants with
prostate cancer that has spread to other places in the body. Addition of prostate removal... expand
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. Addition of prostate removal surgery or radiation therapy to standard systemic therapy for prostate cancer may lower the chance of the cancer growing or spreading. Type: Interventional Start Date: Sep 2018 |
A Phase I/II Clinical Trial of PepCan in Head and Neck Cancer Patients
University of Arkansas
Head and Neck Cancer
This study has been designed to evaluate the safety and efficacy of giving seven injections
of PepCan or placebo over approximately a 24-month period in subjects with head and neck
cancers who achieved remission. PepCan may prove to be beneficial in treating many stages of... expand
This study has been designed to evaluate the safety and efficacy of giving seven injections of PepCan or placebo over approximately a 24-month period in subjects with head and neck cancers who achieved remission. PepCan may prove to be beneficial in treating many stages of HPV-related malignancies starting from infection to cancer. Safety, efficacy in terms of reduced cancer recurrence, immunological responses and profiles, and gut microbiome changes will be assessed. Type: Interventional Start Date: Nov 2019 |
Lower-Dose Chemoradiation in Treating Patients With Early-Stage Anal Cancer, the DECREASE Study
ECOG-ACRIN Cancer Research Group
Anal Basaloid Carcinoma
Anal Canal Cloacogenic Carcinoma
Anal Canal Squamous Cell Carcinoma
Anal Margin Squamous Cell Carcinoma
Stage I Anal Cancer AJCC v8
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation)
therapy works in comparison to standard-dose chemoradiation in treating patients with
early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and
capecitabine,... expand
This phase II trial studies how well lower-dose chemotherapy plus radiation (chemoradiation) therapy works in comparison to standard-dose chemoradiation in treating patients with early-stage anal cancer. Drugs used in chemotherapy, such as mitomycin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. This study may help doctors find out if lower-dose chemoradiation is as effective and has fewer side effects than standard-dose chemoradiation, which is the usual approach for treatment of this cancer type. Type: Interventional Start Date: Nov 2019 |
Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE 301 [Part 1 and Part 2...
Milestone Pharmaceuticals Inc.
Paroxysmal Supraventricular Tachycardia
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to
evaluate the efficacy and safety of etripamil NS self-administered by patients who experience
an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting.
Part 1 comprised... expand
This is a two-part, multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etripamil NS self-administered by patients who experience an episode of paroxysmal ventricular tachycardia (PSVT) in an at-home setting. Part 1 comprised the conduct of the NODE-301 study up to the date of the adjudication of 150th positively adjudicated PSVT episode and Part 2 comprises the conduct of the NODE-301 study after the completion of Part 1. The RAPID Study (NODE-301 - Part 2) will enroll patients enrolled during Part 1 who had not dosed with the double-blind study drug, or had not discontinued the study before the adjudication of the 150th positively adjudicated PSVT episode in Part 1, and patients enrolled into the study following the completion of Part 1. Enrollment will continue until and for approximately 6 months after the date of the adjudication of the 180th positively adjudicated PSVT episode. The study will include the following visits: A Screening Visit, A Test Dose Randomization Visit, Monthly Follow-up Visits, A Randomized Treatment Period, A Randomized Treatment Period Follow-Up Visit, An Open-Label Treatment Period, and A Final Study Visit. Type: Interventional Start Date: Jun 2018 |
Chronic Kidney Disease (CKD) Platelet Study
University of Arkansas
Chronic Kidney Diseases
Heart Attack
Stroke, Ischemic
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic
kidney disease (CKD) compared to people with normal kidneys. In the first part of the study,
half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other... expand
This study evaluates how aspirin, clopidogrel and ticagrelor work in people with chronic kidney disease (CKD) compared to people with normal kidneys. In the first part of the study, half of CKD participants will be randomly assigned to ticagrelor and aspirin, while the other half will be assigned to clopidogrel and aspirin in a blinded fashion. The treatment duration will be two weeks. After recruiting CKD participants the investigator will recruit controls with normal kidney function that will receive only ticagrelor and aspirin for two weeks. Type: Interventional Start Date: Nov 2018 |
Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System
Monteris Medical
Metastatic Brain Tumor
Primary Brain Tumor
Epileptic/Seizure Foci
Movement Disorders
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is
being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS
has been used in over 2600 procedures conducted at over 70 leading institutions across United... expand
The NeuroBlate® System (NBS) is a minimally invasive robotic laser thermotherapy tool that is being manufactured by Monteris Medical. Since it received FDA clearance in May 2009, the NBS has been used in over 2600 procedures conducted at over 70 leading institutions across United States. This is a prospective, multi-center registry that will include data collection up to 5 years to evaluate safety, QoL, and procedural outcomes including local control failure rate, progression free survival, overall survival, and seizure freedom in up to 1,000 patients and up to 50 sites. Type: Observational Start Date: Oct 2015 |
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic...
Insmed Incorporated
Non-Cystic Fibrosis Bronchiectasis
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25
mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week
treatment period.
expand
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period. Type: Interventional Start Date: Dec 2020 |
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
Yale University
Intracerebral Hemorrhage
Atrial Fibrillation
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite
outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with
recent ICH and atrial fibrillation (AF).
Secondary Aim: To determine if apixaban, compared... expand
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale. Type: Interventional Start Date: Jan 2020 |
NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)
NFlection Therapeutics, Inc.
Cutaneous Neurofibroma
Neurofibromatosis 1
This is a randomized, double-blind, vehicle-controlled, parallel group dose response study
evaluating the safety and effectiveness of 2 concentrations of NFX-179 Gel in subjects with
cutaneous neurofibromas. At Visit 1, the investigator will identify 10 Target cNFs that
fulfil... expand
This is a randomized, double-blind, vehicle-controlled, parallel group dose response study evaluating the safety and effectiveness of 2 concentrations of NFX-179 Gel in subjects with cutaneous neurofibromas. At Visit 1, the investigator will identify 10 Target cNFs that fulfil the enrollment criteria. The Target cNFs must be located on the subject's face, anterior trunk, or upper extremities. Two Target cNFs must be on the face and 8 must be on the anterior trunk or upper extremities. The study medication will be applied topically QD to the Target cNFs for 182days (26 weeks). During the duration of the study subjects will be evaluated for safety and efficacy. Type: Interventional Start Date: Sep 2021 |
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade...
National Cancer Institute (NCI)
Renal Pelvis and Ureter Urothelial Carcinoma
This phase III trial compares the effect of adding durvalumab to chemotherapy versus
chemotherapy alone before surgery in treating patients with upper urinary tract cancer.
Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune
system attack... expand
This phase III trial compares the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery may enhance the shrinking of the tumor compared to chemotherapy alone. Type: Interventional Start Date: May 2021 |
Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE
Matthew Neal MD
Covid19
This is a randomized, open label, adaptive platform trial to compare the effectiveness of
antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19
positive inpatients
expand
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients Type: Interventional Start Date: Sep 2020 |
- Previous
- Next